DE69725754D1 - Eingekapselte Antikörper-produzierende Zellen - Google Patents

Eingekapselte Antikörper-produzierende Zellen

Info

Publication number
DE69725754D1
DE69725754D1 DE69725754T DE69725754T DE69725754D1 DE 69725754 D1 DE69725754 D1 DE 69725754D1 DE 69725754 T DE69725754 T DE 69725754T DE 69725754 T DE69725754 T DE 69725754T DE 69725754 D1 DE69725754 D1 DE 69725754D1
Authority
DE
Germany
Prior art keywords
producing cells
encapsulated antibody
antibody
encapsulated
capsules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69725754T
Other languages
English (en)
Other versions
DE69725754T2 (de
Inventor
Marc Piechaczyk
Mireia Pelegrin
Mariana Marin
Robert Saller
Brian Salmons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Centre National de la Recherche Scientifique CNRS
Original Assignee
Bavarian Nordic Research Institute AS
CT NAT de la RECH SCIENT MONTP
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic Research Institute AS, CT NAT de la RECH SCIENT MONTP, Centre National de la Recherche Scientifique CNRS filed Critical Bavarian Nordic Research Institute AS
Publication of DE69725754D1 publication Critical patent/DE69725754D1/de
Application granted granted Critical
Publication of DE69725754T2 publication Critical patent/DE69725754T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69725754T 1996-12-23 1997-12-18 Eingekapselte Antikörper-produzierende Zellen Expired - Lifetime DE69725754T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK149796 1996-12-23
DK149796 1996-12-23
PCT/EP1997/007120 WO1998027966A2 (en) 1996-12-23 1997-12-18 Encapsulated cells producing antibodies

Publications (2)

Publication Number Publication Date
DE69725754D1 true DE69725754D1 (de) 2003-11-27
DE69725754T2 DE69725754T2 (de) 2004-08-19

Family

ID=8105461

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69725754T Expired - Lifetime DE69725754T2 (de) 1996-12-23 1997-12-18 Eingekapselte Antikörper-produzierende Zellen

Country Status (11)

Country Link
US (1) US6426088B1 (de)
EP (1) EP0948319B1 (de)
JP (2) JP4727768B2 (de)
AT (1) ATE252374T1 (de)
AU (1) AU6205998A (de)
DE (1) DE69725754T2 (de)
DK (1) DK0948319T3 (de)
ES (1) ES2208973T3 (de)
PT (1) PT948319E (de)
SI (1) SI0948319T1 (de)
WO (1) WO1998027966A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168339A1 (en) * 1997-01-20 2002-11-14 Marc Piechaczyk Biological material for treating a mammal by antibody gene transfer and pharmaceutical composition containing same
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US20040033212A1 (en) * 2000-07-29 2004-02-19 Thomson Brian Mark Tissue implant
US20040016013A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
US20040014704A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent induces tolerance
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20040220085A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Compositions for nucleic acid delivery
US20040219099A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Method for the treatment of tumors
US20050208032A1 (en) * 2004-01-16 2005-09-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
DE102005011367B4 (de) * 2005-03-11 2010-12-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Cellulosesulfat mit verbesserten Eigenschaften
JP6081374B2 (ja) 2011-01-25 2017-02-15 オーストリアノヴァ シンガポール プライベート リミテッド 酸性劣化からの微生物細胞の保護
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6025929A (ja) * 1983-07-20 1985-02-08 ザ・スト−ル・リサ−チ・アンド・デイベロツプメント・コ−ポレ−シヨン カプセル化細胞、その製造方法および用途
ATE76331T1 (de) * 1987-02-25 1992-06-15 Hoechst Ag Mikroenkapsulierung von biologisch aktivem material.
US5427935A (en) * 1987-07-24 1995-06-27 The Regents Of The University Of Michigan Hybrid membrane bead and process for encapsulating materials in semi-permeable hybrid membranes
US5116747A (en) 1989-08-11 1992-05-26 University Of Waterloo Immobilization of biologically active material in capsules prepared from a water-soluble polymer and chitosan acetate
US5686113A (en) * 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
US5997900A (en) * 1996-04-17 1999-12-07 Wang; Taylor G. Encapsulation system for the immunoisolation of living cells

Also Published As

Publication number Publication date
ATE252374T1 (de) 2003-11-15
JP2009013182A (ja) 2009-01-22
PT948319E (pt) 2004-02-27
EP0948319A2 (de) 1999-10-13
JP2001507344A (ja) 2001-06-05
WO1998027966A2 (en) 1998-07-02
JP4727768B2 (ja) 2011-07-20
SI0948319T1 (en) 2004-04-30
EP0948319B1 (de) 2003-10-22
AU6205998A (en) 1998-07-17
DE69725754T2 (de) 2004-08-19
WO1998027966A3 (en) 1998-11-12
DK0948319T3 (da) 2004-02-09
US6426088B1 (en) 2002-07-30
ES2208973T3 (es) 2004-06-16

Similar Documents

Publication Publication Date Title
NO962088D0 (no) Preparat for in vivo-produksjon av terapeutiske produkter
EP1194164B8 (de) Prion protein peptide und deren verwendung
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
DE69718053D1 (de) in vitro methoden und verwendung von pharmazeutische zusammensetzungen für die BEHANDLUNG VON INNENOHRHAARZELLEN
ATE337019T1 (de) Geladene lipide und deren verwendung
SI1641483T1 (sl) Fuzijski proteini
HUP0002831A3 (en) Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
TR200200785T2 (tr) 8-Fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-on türevleri
DE69725754D1 (de) Eingekapselte Antikörper-produzierende Zellen
MX9602750A (es) Proteinas de la region v receptoras de antigenos de la celula t y metodos para la preparacion de las mismas.
TR200100637T2 (tr) Yeni doğal ürün türevleri
DE59610251D1 (de) Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
TR200401775T4 (tr) 3-Amino-1-Fenil-1H[1,2,4] triazol'ün dallanmış değiştirilmiş yeni amino türevleri, bunların imali için metot ve bunları içeren farmosötik (eczacılık) bileşimleri
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
BR9809712A (pt) Formas de dosagem de sertralina em solução encapsulada de gelatina
WO2000042987A3 (en) Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections
TR199901385T2 (xx) Piperidin t�revleri.
PT1105503E (pt) Guanililciclase humana soluvel alfal/betal (hsgc alfal/betal) isolada e purificada
HK1035206A1 (en) Delivery of therapeutic proteins via implantation of genetically modified cells in the omentum.
DE50013908D1 (de) Zytotoxisches t-zellepitop des papillomavirus l1-proteins und seine verwendung in diagnostik und therapie
TR199800705T2 (de)
BR1100724A (pt) Fornecimento in vivo de neurotransmissores por meio de células encapsuladas implantadas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, MONT

Owner name: BAVARIAN NORDIC A/S,, KVISTGARD, DK